Tenaya Therapeutics Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Tenaya Therapeutics's estimated annual revenue is currently $20.9M per year.(i)
  • Tenaya Therapeutics's estimated revenue per employee is $139,500
  • Tenaya Therapeutics's total funding is $248M.
  • Tenaya Therapeutics's current valuation is $412.8M. (January 2022)

Employee Data

  • Tenaya Therapeutics has 150 Employees.(i)
  • Tenaya Therapeutics grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Tenaya Therapeutics is a privately-held biopharmaceutical company backed by The Column Group. The Company was founded in 2016 by world-leading scientists from the Gladstone Institute's Cardiovascular Division and the University of Texas Southwestern Medical Center. Tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. Tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Tenaya Therapeutics News

2022-04-19 - Catalyst watch: Apple earnings, Twitter drama and media eyes ...

(WVE), Century Therapeutics (IPSC), Achilles Therapeutics plc (ACHL), Taysha Gene Therapies (TSHA), Passage Bio (PASG) and Tenaya Therapeutics (...

2022-04-06 - Retro Biosciences raises $180M, aims to add 10 years of ...

... cellular reprogramming, purging damaged cells and plasma-derived therapies. ... including Tenaya Therapeutics in South San Francisco;...

2022-03-22 - Tenaya Therapeutics Reports Fourth Quarter and Year-End ...

--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially...

2021-03-02 - Tenaya Therapeutics secures $106M

Tenaya Therapeutics has raised a $106 million Series C led by RTW Investments. The Bay Area company is developing therapies to address cardiovascular disease, with a focus on gene therapy, cellular regeneration and precision medicine. Tenaya raised $92 million at a $210 million valuation in 2019 ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding